EGFR and non-small cell lung carcinoma: More recently, the phase II LUMINOSITY study with Teliso-V demonstrated an ORR of 28.6% (95% CI, 21.7–36.2) in patients with previously treated MET-overexpressing advanced nonsquamous EGFR-wild-type (WT) NSCLC.